Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

NCT07540572 is registered in ClinicalTrials.gov with IDEAYA Biosciences as lead sponsor.

NCT NCT07540572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07540572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer
Lead sponsor
IDEAYA Biosciences
Phase
Phase 1
Overall status
Recruiting
Start date
March 17, 2026
Completion date
June 30, 2030
Enrollment
160 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer (crpc), er+, her 2- breast cancer, microsatellite stable (mss) colorectal carcinoma, non-small cell lung cancer (nsclc)